[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100075033":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":7,"locations":19,"responsibleParty":7,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":7,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":7,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"ARCAGY\u002F GINECO GROUP","OTHER",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Paraplatin",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Paclitaxel",[15],{"name":16,"affiliation":17,"role":18},"Gilles Freyer, MD, PhD","Centre Hospitalier Lyon-Sud 69495 Pierre-Bénite cedex","PRINCIPAL_INVESTIGATOR",[20,32],{"facility":21,"status":7,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Centre Hosptalier Emile Roux","Eaubonne","95600","France","FR",{"type":27,"coordinates":28},"Point",[29,30],2.28249,48.99712,{"lat":30,"lon":29},{"facility":33,"status":7,"city":34,"state":7,"zip":35,"country":24,"countryCode":25,"cosmosGeoPoint":36,"geoPoint":40,"contacts":7},"Centre Hospitalier Lyon-sud","Pierre-Bénite","69495",{"type":27,"coordinates":37},[38,39],4.82424,45.70359,{"lat":39,"lon":38},"100075033","phase-2-evaluation-of-the-safety-and-efficacy-of-paraplatin-in-combination-with-taxol-in-patients-of-70-years-and-older-with-ovary-cancer-figo-stages-iii-iv-100075033",false,"NCT00231075","Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV","National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2","Inclusion Criteria:\n\n* Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages III or IV (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased CA-125 must be diagnosed simultaneously)\n* Patient aged \\> 70 years\n* Neutrophil polynuclears \\> 1500\u002Fmm3 and Platelets \\> 100 000\u002Fmm3\n* No clinical icterus\n* Life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Previous diagnosis of malignancy\n* Previous chemotherapy treatment\n* Previous radiotherapy\n* Hypersensitivity to products containing Cremophore EL\n* Hepatic values: bilirubine \\> 2\\*LSN, SGOT-SGPT \\> 2\\*LSN and\u002For Alkalin phosphatase \\> 3\\*LSN\n* Myocardiopathy with arrhythmia","FEMALE","70 Years",{"count":51,"type":7},75,"INTERVENTIONAL",[54],"PHASE2","Safety and Efficacy of Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary cancer F.I.G.O. stages III and IV.",[57],"Ovarian Cancer",[59,60],"Epithelial ovary cancer F.I.G.O. stages III or IV","70 years or older","COMPLETED","2005-11-02",{"date":64,"type":65},"2005-11-03","ESTIMATED",{"date":67,"type":7},"2001-01",{"date":69,"type":7},"2007-05",{"name":5,"class":6},2]